Subcutaneous Immunotherapy (SCIT): The Clinical Pharmacology Guide

Subcutaneous immunotherapy (SCIT) means allergen immunotherapy delivered by injection into the subcutaneous tissue — the fatty layer beneath the skin but above the muscle. This route is contrasted with intramuscular injection (into muscle), intradermal injection (into the skin layer itself, used for allergy testing), and sublingual administration (under the tongue, used in SLIT). The subcutaneous route for SCIT was chosen because it engages dermal myeloid dendritic cells that drive tolerogenic immune responses in draining lymph nodes. Subcutaneous injection of allergen extract reaches blood levels sufficient to modulate systemic IgE responses while maintaining the controlled presentation that promotes tolerance rather than allergic reaction. This is why SCIT requires lower allergen doses than sublingual immunotherapy — the route is immunologically more efficient, though also carries higher systemic reaction risk.

Subcutaneous immunotherapy and intradermal allergy testing both involve injecting allergen preparations into the body, but they serve completely different purposes. Allergy skin testing (CPT 95004 for percutaneous; CPT 95024 for intradermal) introduces tiny amounts of allergen into or just beneath the epidermis to observe the local wheal-and-flare response — a diagnostic procedure that confirms IgE sensitization. SCIT delivers allergen formulations into the subcutaneous fat with the goal of immune tolerance induction, using doses that escalate over weeks and months to therapeutic levels. The volumes, concentrations, route depths, and clinical goals are entirely different. Skin testing uses very small volumes (0.01-0.05 mL) of concentrated extract; SCIT build-up starts at 1,000 to 10,000-fold dilutions and slowly escalates to the 0.5 mL maintenance volume.

The FDA has standardized only 19 of approximately 1,200 commercially available allergenic source materials. Standardized extracts include 8 grass pollen preparations (measured in BAU/mL), short ragweed extract (measured in Amb a 1 units/mL, approximately 100,000 AU/mL), two house dust mite species — Dermatophagoides pteronyssinus and D. farinae (measured in AU/mL; typically 10,000 AU/mL concentrate), two cat hair and dander preparations (measured in BAU/mL; typically 10,000 BAU/mL concentrate), and six Hymenoptera venoms (yellow jacket, mixed vespid, honeybee, white-faced hornet, yellow hornet, fire ant). All other commonly used allergens — tree pollens, weed pollens other than ragweed, mold species, dog dander, cockroach, most food proteins — are non-standardized, sold in PNU or weight/volume units that do not reliably reflect major allergen content.

The AAAAI/ACAAI Practice Parameter specifies a maintenance dose range of 5-20 micrograms of the major allergen for inhalant allergens and 100 micrograms per venom protein for Hymenoptera immunotherapy. Individual allergen-specific studies define tighter targets within this range: approximately 15 micrograms of Fel d 1 for cat immunotherapy (Nanda et al., JACI 2004), 7-12 micrograms of Der p 1 for house dust mite, 6-24 micrograms of Amb a 1 for short ragweed (Creticos et al., NEJM 1996), and 7-19 micrograms of Phl p 5 for timothy grass. In product-specific units, this translates to 500-2,000 AU per 0.5 mL injection for dust mite, and 1,000-4,000 BAU per 0.5 mL for standardized grass and cat extracts. Venom immunotherapy maintenance is 100 micrograms per venom protein, administered every 4-6 weeks and extendable to 12 weeks after the first year.

For decades subcutaneous immunotherapy was administered only in a clinic, because subcutaneous allergen delivery carries a real systemic-reaction risk: roughly 0.1% of injection visits produce systemic reactions, about 85% within 30 minutes of injection. The AAAAI/ACAAI Practice Parameter is built around having epinephrine on hand and a physician available to manage that risk. Telehealth-supervised programs such as Curex now reproduce those safeguards at home for eligible maintenance patients: the serum is sterile-compounded to USP <797> and prescribed by a board-certified allergist, the patient keeps a prescribed epinephrine auto-injector confirmed on hand, doses escalate gradually week by week, and the first injection and every dose change are supervised live over Zoom — with a brief self-observation period afterward. Candidacy is confirmed by the allergist; this is for eligible patients, not everyone, and is distinct from FDA-approved SLIT tablets and off-label compounded drops, which differ in route and risk.

Allergy shots are subcutaneous injections — administered into the fatty tissue just beneath the skin, not into muscle. The subcutaneous layer is targeted specifically because it is rich in dendritic cells that capture allergen and present it in regional lymph nodes in a tolerogenic context. Intramuscular injection would deliver allergen into muscle tissue, where it would be absorbed more rapidly and potentially present to different antigen-presenting cell populations. The practical technique: the injection site is the posterolateral upper arm, the skin is gently raised between thumb and forefinger (or not, depending on body habitus and needle length), and the 26-27 gauge needle is inserted at approximately 45-90 degrees to the skin surface into the subcutaneous fat. Depth is typically 5-8mm; inadvertent intramuscular injection is a documented cause of increased systemic reaction rates.